SEARCH

SEARCH BY CITATION

References

  • 1
    London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:173140.
  • 2
    Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010;77:110714.
  • 3
    Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2:12418.
  • 4
    Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011;109:697711.
  • 5
    Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009;20:145364.
  • 6
    Rensen SSM, Doevendans PAFM, van Eys GJJM. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J 2007;15:1008.
  • 7
    Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000;102:263642.
  • 8
    Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:e107.
  • 9
    Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010;21:10312.
  • 10
    Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol 2011;300:C21020.
  • 11
    Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011;109:e112.
  • 12
    Zeidan A, Nordström I, Dreja K, Malmqvist U, Hellstrand P. Stretch-dependent modulation of contractility and growth in smooth muscle of rat portal vein. Circ Res 2000;87:22834.
  • 13
    Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide M et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol 2009;297:H167384.
  • 14
    Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KA, O'Neill WC. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004;15:1392401.
  • 15
    Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:5208.
  • 16
    Drury AN, Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 1929;68:21337.
  • 17
    Burnstock G. Purinergic signalling. Br J Pharmacol 2006;147:S17281.
  • 18
    Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:117989.
  • 19
    Wang L, Karlsson L, Moses S, Hultgårdh-Nilsson A, Andersson M, Borna C et al. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2002;40:84153.
  • 20
    Wang L, Andersson M, Karlsson L, Watson MA, Cousens DJ, Jern S et al. Increased mitogenic and decreased contractile P2 receptors in smooth muscle cells by shear stress in human vessels with intact endothelium. Arterioscler Thromb Vasc Biol 2003;23:13706.
  • 21
    Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008;4:120.
  • 22
    Schuchardt M, Prüfer J, Prüfer N, Wiedon A, Huang T, Chebli M et al. The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y2-mediated pro-inflammatory signalling by monocyte chemoattractant protein-1 formation. J Mol Med 2011;89:799810.
  • 23
    Zimmermann H, Zebisch M, Sträter N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012;8:437502.
  • 24
    Mackenzie NCW, Huesa C, Rutsch F, MacRae VE. New insights into NPP1 function: lessons from clinical and animal studies. Bone 2012;51:9618.
  • 25
    Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 1992;26:407.
  • 26
    Lew MJ, White TD. Release of endogenous ATP during sympathetic nerve stimulation. Br J Pharmacol 1987;92:34955.
  • 27
    Bodin P, Burnstock G. ATP-stimulated release of ATP by human endothelial cells. J Cardiovasc Pharmacol 1996;27:8725.
  • 28
    Katsuragi T, Tokunaga T, Ogawa S, Soejima O, Sato C, Furukawa T. Existence of ATP-evoked ATP release system in smooth muscles. J Pharmacol Exp Ther 1991;259:5138.
  • 29
    Lohman AW, Billaud M, Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovas Res 2012;95:26980.
  • 30
    Fleisch H, Schibler D, Maerki J, Frossard I. Inhibition of aortic calcification by means of pyrophosphate and polyphosphates. Nature 1965;207:13001.
  • 31
    Francis MD. The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 1969;3:15162.
  • 32
    O'Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011;79:5127.
  • 33
    Riser BL, Barreto FC, Rezg R, Valaitis PW, Cook CS, White JA et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011;26:334957.
  • 34
    O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010;25:18791.
  • 35
    Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005;16:2495500.
  • 36
    Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet 2003;34:37981.
  • 37
    Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 2008;1:13340.
  • 38
    Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010;86:2738.
  • 39
    Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010;86:26772.
  • 40
    Eller P, Hochegger K, Feuchtner GM, Zitt E, Tancevski I, Ritsch A et al. Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant 2008;23:3217.
  • 41
    Hosoda Y, Yoshimura Y, Hiqaki S. A new breed of mouse showing multiple osteochondral lesions – twy mouse. Ryumachi 1981;21(Suppl):15764.
  • 42
    Sakamoto M, Hosoda Y, Kojimahara K, Yamazaki T, Yoshimura Y. Arthritis and ankylosis in twy mice with hereditary multiple osteochondral lesions: with special reference to calcium deposition. Pathol Int 1994;44:4207.
  • 43
    Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998;19:2713.
  • 44
    Sali A, Favaloro J, Terkeltaub R, Goding J. Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cellmembrane glycoprotein-1 (PC-1) produces abnormal calcification of periarticular tissues. In: Vanduffel L, Lemmems R, editors. Ecto-ATPases and Related Ectoenzymes. Maastrich, the Netherlands: Shaker Publishing; 1999: pp 26782.
  • 45
    Mackenzie NCW, Zhu D, Milne EM, van't Hof R, Martin A, Quarles DL et al. Altered bone development and an increase in FGF-23 expression in Enpp1−/− mice. PLoS One 2012;7:e32177.
  • 46
    Zhu D, Mackenzie NCW, Millan JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011;6:e19595.
  • 47
    Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012;7:201725.
  • 48
    ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:3458.
  • 49
    Anderson HC, Harmey D, Camacho NP, Garimella R, Sipe JB, Tague S et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 2005;166:171120.
  • 50
    Prosdocimo DA, Wyler SC, Romani AM, O'Neill WC, Dubyak GR. Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol 2010;298:C70213.
  • 51
    Huang MS, Sage AP, Lu J, Demer LL, Tintut Y. Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem Biophys Res Commun 2008;374:5538.
  • 52
    Côté N, Husseini DE, Pépin A, Guauque-Olarte S, Ducharme V, Bouchard-Cannon P et al. ATP acts as a survival signal and prevents the mineralization of aortic valve. J Mol Cell Cardiol 2012;52:1191202.
  • 53
    Cote N, Husseini DE, Pepin A, Bouvet C, Gilbert LA, Audet A et al. Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats. Eur J Pharmacol 2012;689:13946.
  • 54
    Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S et al. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000;279:R136577.
  • 55
    Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000;289:26570.
  • 56
    Nürnberg P, Thiele H, Chandler D, Höhne W, Cunningham ML, Ritter H et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001;28:3741.
  • 57
    Williams CJ, Zhang Y, Timms A, Bonavita G, Caeiro F, Broxholme J et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002;71:98591.
  • 58
    Villa-Bellosta R, Wang X, Millán JL, Dubyak GR, O'Neill WC. Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2011;301:H618.
  • 59
    Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005;19:1093104.
  • 60
    Zhao G, Xu MJ, Zhao MM1, Dai XY, Kong W, Wilson GM et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012;82:3444.
  • 61
    Mornet E. Hypophosphatasia. Orphanet J Rare Dis 2007;2:40.
  • 62
    Russell RG, Bisaz S, Donath A, Morgan DB, Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest 1971;50:9619.
  • 63
    Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS et al. Alkaline phosphatase knock_out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999;14:201526.
  • 64
    Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008;73:102430.
  • 65
    Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millan JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007;22:170010.
  • 66
    St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F et al. NT5E mutations and arterial calcifications. N Engl J Med 2011;364:43242.
  • 67
    Robson SC. Role of CD73 and extracellular adenosine in disease. Purinergic Signal 2011;7:36772.
  • 68
    Robson SC, Sevigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006;2:40930.
  • 69
    Robson SC, Wu Y, Sun XF, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005;31:21733.
  • 70
    Kauffenstein G, Fürstenau CR, D'Orleans-Juste P, Sévigny J. The ecto-nucleotidase NTPDase1 differentially regulates P2Y1 and P2Y2 receptor-dependent vasorelaxation. Br J Pharmacol 2010;159:57685.
  • 71
    Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D'Orleans-Juste P et al. NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 2010;85:20413.
  • 72
    Schuchardt M, Tölle M, van der Giet M. P2Y purinoceptors as potential emerging therapeutical target in vascular disease. Curr Pharm Des 2012;18:616980.
  • 73
    Schuchardt M, Tolle M, Prufer J, Prufer N, Huang T, Jankowski V et al. Uridine adenosine tetraphosphate activation of the purinergic receptor P2Y enhances in vitro vascular calcification. Kidney Int 2012;81:25665.
  • 74
    Matsumoto T, Tostes RC, Webb RC. The role of uridine adenosine tetraphosphate in the vascular system. Adv Pharmacol Sci 2011;2011:435132.
  • 75
    Erlinge D, Hou M, Webb TE, Barnard EA, Möller S. Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun 1998;248:86470.
  • 76
    Osman L, Chester AH, Amrani M, Yacoub MH, Smolenski RT. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation 2006;114(1 Suppl):I5661572.
  • 77
    Orriss IR, Utting JC, Brandao-Burch A, Colston K, Grubb BR, Burnstock G et al. Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology 2007;148:420816.
  • 78
    Orriss IR, Burnstock G, Arnett TR. Purinergic signalling and bone remodelling. Curr Opin Pharmacol 2010;3:32230.
  • 79
    Grol MW, Panupinthu N, Korcok J, Sims SM, Dixon SJ. Expression, signalling, and function of P2X7 receptors in bone. Purinergic Signal 2009;5:20521.
  • 80
    Gartland A, Skarratt KK, Hocking LJ, Parsons C, Stokes L, Jorgensen NR et al. Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet 2012;20:55964.